SAB Biotherapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

SAB Biotherapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $10.50 million for the year ending 2025.

  • SAB Biotherapeutics, Inc. showed an increase of +18.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from SAB Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2020 to 2025), SAB Biotherapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 16.7%.
  • Historical annual values: Fiscal year 2025: $10.50 million | Fiscal year 2024: $8.90 million | Fiscal year 2023: $56.57 million | Fiscal year 2022: $15.05 million | Fiscal year 2022: $16.62 million | Fiscal year 2022: $22.41 million | Fiscal year 2021: $33.21 million | Fiscal year 2020: $12.61 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: